Recon: Novo follows Lilly in slashing US insulin prices; FDA staff signal support for Pfizer’s COVID drug in high-risk patients
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy